Trial Profile
A Study Assessing The Real-Life Safety And Efficacy Of Natalizumab In Hungarian Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 04 May 2017 New trial record
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.